TY - JOUR
T1 - Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis
AU - Kang, Kefei
AU - Cooper, Kevin D.
AU - Hanifin, Jon M.
N1 - Funding Information:
In a double-blind prospective study, eighteen patients with atopic dermatitis (AD) were treated with thrice-weekly injections of 50 mg thymopoietin pentapeptide (TP-5) or placebo for 6 weeks. Clinical parameters, lymphocyte subsets defined by monoclonal antibodies, and serum IgE were modified. Younger patients (age <34) responded to TP-5 with much greater improvement in severity scores than TP-5-treated patients of age >34 or than placebo-treated patients of either age group (p < 0.05). Both absolute lymphocytes and OKT8 + cytotoxic/suppressor cells were significantly increased (p < 0.05) in the TP-5 group, whereas they were not significantly increased in the placebo group (p > 0.05). Conversely, Ia + cells were significantly increased in the placebo group (p < 0.05), but remained the same in the TP-5 group (p > 0.05). Serum IgE levels were not significantly altered in either group. Thus, TP-5 had a beneficial clinical effect in AD, especially in younger patients, and increased the reduced OKT8 + cytotoxic/suppressor T cells and prevented an increase of Ia + cells during pollen season. (J AM ACAD DERMATOL 8:372-377, 1983.) From the Department of Dermatology, Oregon Health Sciences Uni-versity. Supported by National Institute of Health Grants 4-R01 A1 155557 and 5 T32 AMO 7153, Medical Research Foundation of Oregon Grant 28.21, and by a grant from Ortho Pharmaceutical Corp., Raritan, NJ. Accepted for publication July 15, 1982.
PY - 1983
Y1 - 1983
N2 - In a double-blind prospective study, eighteen patients with atopic dermatitis (AD) were treated with thrice-weekly injections of 50 mg thymopoietin pentapeptide (TP-5) or placebo for 6 weeks. Clinical parameters, lymphocyte subsets defined by monoclonal antibodies, and serum IgE were modified. Younger patients (age ¼ 34) responded to TP-5 with much greater improvement in severity scores than TP-5-treated patients of age 〉34 or than placebo-treated patients of either age group (p ¼ 0.05). Both absolute lymphocytes and OKT8+ cytotoxic/suppressor cells were significantly increased (p ¼ 0.05) in the TP-5 group, whereas they were not significantly increased in the placebo group (p>0.05). Conversely, Ia+ cells were significantly increased in the placebo group (p<0.05), but remained the same in the TP-5 group (p>0.05). Serum IgE levels were not significantly altered in either group. Thus, TP-5 had a beneficial clinical effect in AD, especially in younger patients, and increased the reduced OKT8+ cytotoxic/suppressor T cells and prevented an increase of Ia+ cells during pollen season.
AB - In a double-blind prospective study, eighteen patients with atopic dermatitis (AD) were treated with thrice-weekly injections of 50 mg thymopoietin pentapeptide (TP-5) or placebo for 6 weeks. Clinical parameters, lymphocyte subsets defined by monoclonal antibodies, and serum IgE were modified. Younger patients (age ¼ 34) responded to TP-5 with much greater improvement in severity scores than TP-5-treated patients of age 〉34 or than placebo-treated patients of either age group (p ¼ 0.05). Both absolute lymphocytes and OKT8+ cytotoxic/suppressor cells were significantly increased (p ¼ 0.05) in the TP-5 group, whereas they were not significantly increased in the placebo group (p>0.05). Conversely, Ia+ cells were significantly increased in the placebo group (p<0.05), but remained the same in the TP-5 group (p>0.05). Serum IgE levels were not significantly altered in either group. Thus, TP-5 had a beneficial clinical effect in AD, especially in younger patients, and increased the reduced OKT8+ cytotoxic/suppressor T cells and prevented an increase of Ia+ cells during pollen season.
UR - http://www.scopus.com/inward/record.url?scp=0020693446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020693446&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(83)70042-3
DO - 10.1016/S0190-9622(83)70042-3
M3 - Article
C2 - 6339571
AN - SCOPUS:0020693446
VL - 8
SP - 372
EP - 377
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 3
ER -